Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2005 2
2014 1
2017 2
2018 5
2019 4
2020 6
2021 6
2022 4
2023 1
2024 2
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
Treatment of non-Hodgkin lymphoma with point-of-care manufactured CAR T cells: a dual institution, phase 1 trial.
Ghobadi A, Caimi PF, Reese JS, Goparaju K, di Trani M, Ritchey J, Jackson Z, Tomlinson B, Schiavone JM, Kleinsorge-Block S, Zamborsky K, Eissenberg L, Schneider D, Boughan KM, Zabor EC, Metheny L, Gallogly M, Kruger W, Kadan M, Worden A S A, Sharma A, Cooper BW, Otegbeye F, Sekaly RP, Wald DN, Carlo-Stella C, DiPersio J, Orentas R, Dropulic B, de Lima M. Ghobadi A, et al. Among authors: otegbeye f. EClinicalMedicine. 2025 Mar 4;81:103138. doi: 10.1016/j.eclinm.2025.103138. eCollection 2025 Mar. EClinicalMedicine. 2025. PMID: 40115173 Free PMC article.
Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-year follow up.
Portuguese AJ, Huang JJ, Jeon Y, Taheri M, Albittar A, Liang EC, Hirayama AV, Kimble EL, Iovino L, Poh C, Gopal AK, Shadman M, Till BG, Milano F, Chapuis AG, Otegbeye F, Cassaday RD, Basom RS, Wu QV, Maloney DG, Gauthier J. Portuguese AJ, et al. Among authors: otegbeye f. Haematologica. 2025 Mar 13. doi: 10.3324/haematol.2024.287010. Online ahead of print. Haematologica. 2025. PMID: 40079097 Free article.
Development and validation of predictive models of early immune effector cell-associated hematotoxicity.
Liang EC, Huang JJ, Portuguese AJ, Ortiz-Maldonado V, Albittar A, Wuliji N, Basom R, Jeon Y, Wu Q, Torkelson A, Kirchmeier D, Chutnik A, Pender B, Sorror M, Hill JA, Kopmar NE, Banerjee R, Cowan AJ, Green D, Gopal AK, Poh C, Shadman M, Hirayama AV, Till BG, Kimble EL, Iovino L, Chapuis AG, Otegbeye F, Cassaday RD, Milano F, Turtle CJ, Maloney DG, Gauthier J. Liang EC, et al. Among authors: otegbeye f. Blood Adv. 2025 Feb 11;9(3):606-616. doi: 10.1182/bloodadvances.2024014455. Blood Adv. 2025. PMID: 39626349 Free PMC article.
Flow cytometry of DNMT1 as a biomarker of hypomethylating therapies.
Woost PG, William BM, Cooper BW, Ueda Oshima M, Otegbeye F, De Lima MJ, Wald D, Mahfouz RZ, Saunthararajah Y, Stefan T, Jacobberger JW. Woost PG, et al. Among authors: otegbeye f. Cytometry B Clin Cytom. 2024 Jan;106(1):11-24. doi: 10.1002/cyto.b.22158. Epub 2024 Feb 12. Cytometry B Clin Cytom. 2024. PMID: 38345160 Free PMC article.
A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia.
Metheny LL, Sobecks R, Cho C, Fu P, Margevicius S, Wang J, Ciarrone L, Kopp S, Convents RD, Majhail N, Caimi PF, Otegbeye F, Cooper BW, Gallogly M, Malek E, Tomlinson B, Gerds AT, Hamilton B, Giralt S, Perales MA, de Lima M. Metheny LL, et al. Among authors: otegbeye f. Blood Adv. 2024 Mar 26;8(6):1384-1391. doi: 10.1182/bloodadvances.2023011514. Blood Adv. 2024. PMID: 38170741 Free PMC article.
Phase I study of intra-osseous co-transplantation of a single-unit cord blood and mesenchymal stromal cells with reduced intensity conditioning regimens.
Wang J, Sanati F, Firoozmand A, Fu P, Kolk M, Reese-Koc J, de Lima M, Boughan K, Cooper B, Caimi P, Gallogly M, Otegbeye F, Tomlinson B, Metheny L. Wang J, et al. Among authors: otegbeye f. Front Oncol. 2023 May 3;13:1186532. doi: 10.3389/fonc.2023.1186532. eCollection 2023. Front Oncol. 2023. PMID: 37207167 Free PMC article.
Nomenclature for Cellular and Genetic Therapies: A Need for Standardization.
Sharma A, Farnia S, Otegbeye F, Rinkle A, Shah J, Shah NN, Gill S, Maus MV. Sharma A, et al. Among authors: otegbeye f. Transplant Cell Ther. 2022 Dec;28(12):795-801. doi: 10.1016/j.jtct.2022.08.029. Epub 2022 Sep 2. Transplant Cell Ther. 2022. PMID: 36058548 Free PMC article.
Natural Killer Cell Alloreactivity Predicted By Killer Cell Immunoglobulin-Like Receptor Ligand Mismatch Does Not Impact Engraftment in Umbilical Cord Blood and Haploidentical Stem Cell Transplantation.
Otegbeye F, Vina MAF, Wang T, Bolon YT, Lazaryan A, Beitinjaneh A, Bhatt VR, Castillo P, Marsh SGE, Hildebrandt GC, Assal A, Brown VI, Hsu J, Spellman S, de Lima M, Lee SJ. Otegbeye F, et al. Transplant Cell Ther. 2022 Aug;28(8):483.e1-483.e7. doi: 10.1016/j.jtct.2022.05.034. Epub 2022 May 26. Transplant Cell Ther. 2022. PMID: 35643351 Free PMC article.
Targeted Marrow Irradiation Intensification of Reduced-Intensity Fludarabine/Busulfan Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation.
Ali N, Sharma AA, de Rezende ACP, Otegbeye F, Latif BM, Kerbauy MN, Cooper BW, Sanchez G, Metheny L, Bal SK, Sakuraba R, Tomlinson BK, Boughan KM, Kerbauy L, Malek E, Ribeiro AF, Gallogly M, Mansur D, Pereira G, Weltman E, Sekaly RP, de Lima M, Caimi PF, Hamerschlak N. Ali N, et al. Among authors: otegbeye f. Transplant Cell Ther. 2022 Jul;28(7):370.e1-370.e10. doi: 10.1016/j.jtct.2022.04.001. Epub 2022 Apr 11. Transplant Cell Ther. 2022. PMID: 35421620 Free article. Clinical Trial.
34 results